Ge Longhui, May 24, 丨 Hewang Pharmaceutical (00013.HK) announced today that it will announce the latest and updated data from several studies on compounds independently developed by Huhuang Pharmaceutical at the 2024 Annual Meeting of the American Society of Clinical Oncology (“ASCO”) to be held in Chicago, Illinois, USA from May 31 to June 4, 2024.

Following the publication of preliminary data from the FRUTIGA phase III study on second-line treatment of gastric cancer with fruquintinib in February 2024 (ASCO Clinical Oncology Series Session), further updated efficacy data and quality of life data for key subgroups of the study will be presented at this year's ASCO annual meeting. In addition, further data from the FRESCO and FRESCO-2 colorectal cancer phase III studies, surufatinib combination therapy for small cell lung cancer, and preliminary clinical data on the ERK1/2 inhibitor HMPL-295 will also be announced at the conference.